Eculizumab shown effective in aquaporin-4-positive NMOSD

• Posted on: May 22 2019
• By: Saratoga Opthalmology
• Leave a response

This phase 3 randomized controlled trial assessed the efficacy of eculizumab, a terminal complement inhibitor, for reducing relapse frequency in aquaporin-4–positive neuromyelitis optica spectrum disorder (NMOSD).
Source: AAO

Posted in: Uncategorized